Trastuzumab Deruxtecan Secures EU Approval for Residual HER2-Positive Early Breast Cancer Following DESTINY-Breast05 Survival-Free Disease Benefit
FASCO 2027: Recognizing Dedication to Oncology
ASCO 2026.3.4 Living Guideline: Lorlatinib Takes Priority in First-Line ALK-Positive NSCLC After Landmark Seven-Year CROWN Results
A New Chance to Prevent Recurrence: EU Approves Trastuzumab Deruxtecan for HER2-Positive Early Breast Cancer
Arun Azad: New TALAPRO-2 Data Highlight the Prognostic Value of ctDNA and CTCs in Prostate Cancer
Top Gastroesophageal Cancer Updates From ESMO 2026
Jeff Dunn on Cancer Equity: The Powerful Message Behind “Poverty Is a Carcinogen”
Carla Ferrell and Sista Strut 2026: Breast Cancer Awareness Mission
